A clinical study of gene expression models for predicting chemotherapeutic response in patients with esophageal squamous cell carcinoma

A clinical study of gene expression models for predicting chemotherapeutic response in patients with esophageal squamous cell carcinoma - Development of the prediction model for chemoresistance in esophageal cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007750

Enrollment

100

Registered

2012-04-16

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who are suitable for a combination chemotherapy with cisplatin and 5-FU as a first-line treatment in esophageal squamous cell carcinoma.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who are suitable for combination chemotherapy with cisplatin and 5-FU as a first-line treatment in esophageal squamous cell carcinoma. 2)Adequate organ functions; CCr (or e-GFR) >=60ml/minute; no abnormal findings or no need for treatment 3)Adult patients aged 20 years or older 4)Written informed consent obtained

Exclusion criteria

Exclusion criteria: 1)Not meeting the standards of eligibility 2)Pregnant female 3)Treated with combined radiotherapy or other anticancer drugs 4)Any other inappropriate state for participating to this study estimated by doctor in charge

Design outcomes

Primary

Measure	Time frame
Tumor response	—

Countries

Japan

Contacts

Public ContactHitomi Yamagami

Koshin Chemical Inc. Division of Business Development

nomura-hitomi@koshin-chem.co.jp

Outcome results